Comparative Pharmacology
Head-to-head clinical analysis: TRI NORINYL 21 DAY versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI NORINYL 21 DAY versus WOLFINA.
TRI-NORINYL 21-DAY vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects, increases viscosity of cervical mucus, alters endometrial morphology, and inhibits ovulation.
Not specified in available data; likely unapproved or investigational drug.
One tablet (35 mcg ethinyl estradiol, 0.5 mg norethindrone for 7 days, 1 mg norethindrone for 9 days, 0.5 mg norethindrone for 5 days) orally once daily for 21 days, then 7 days off. Start on first day of menstrual period or first Sunday after onset.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-23 hours. Steady-state reached within 5-7 days; clinical relevance for missed dose timing and resumption of ovulation.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~50-60% (as metabolites); Fecal: ~30-40% (via bile); unchanged drug <1%.
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive